Table 3.
Clinicopathologic characteristics and immunohistochemical stain results of 190 HCCs
| SALL4 |
p-value | K19a |
p-value | EpCAMa |
p-value | ||||
|---|---|---|---|---|---|---|---|---|---|
| Negative | Positive | Negative | Positive | Negative | Positive | ||||
| Frequency | 151 (79.5) | 39 (20.5) | 159 (84.1) | 30 (15.9) | 97 (51.3) | 92 (48.7) | |||
| Age (yr) | .858 | .694 | .020 | ||||||
| < 60 | 81 (53.6) | 20 (51.3) | 83 (52.2) | 17 (56.7) | 43 (44.3) | 57 (62.0) | |||
| ≥ 60 | 70 (46.4) | 19 (48.7) | 76 (47.8) | 13 (43.3) | 54 (55.7) | 35 (38.0) | |||
| Sex | 1.000 | .808 | .113 | ||||||
| Male | 32 (21.2) | 8 (20.5) | 33 (20.8) | 7 (23.3) | 16 (16.5) | 24 (26.1) | |||
| Female | 119 (78.8) | 31 (79.5) | 126 (79.2) | 23 (76.7) | 81 (83.5) | 68 (73.9) | |||
| Etiology | .319 | .829 | .010 | ||||||
| Hepatitis B virus–related | 40 (26.5) | 14 (35.9) | 45 (29.3) | 9 (30.0) | 36 (37.1) | 18 (19.6) | |||
| Non-hepatitis B virus–related | 111 (73.5) | 25 (64.1) | 114 (71.7) | 8 (70.0) | 61 (62.9) | 74 (80.3) | |||
| Serum α-fetoprotein (IU/mL) (n = 132) | 1.000 | .032 | .023 | ||||||
| < 1,000 | 76 (76) | 25 (78.1) | 86 (80.4) | 14 (58.3) | 54 (85.7) | 46 (79.3) | |||
| ≥ 1,000 | 24 (24) | 7 (21.9) | 21 (19.6) | 10 (41.7) | 9 (14.3) | 22 (20.7) | |||
| Multiplicity | .825 | .328 | .372 | ||||||
| Absent | 120 (79.5) | 32 (82.1) | 129 (81.1) | 22 (73.3) | 80 (82.5) | 71 (77.2) | |||
| Present | 31 (20.5) | 7 (17.9) | 30 (18.9) | 8 (26.7) | 17 (17.5) | 21 (22.8) | |||
| Tumor size (cm)b | .432 | .076 | .873 | ||||||
| < 5 | 105 (69.5) | 30 (76.9) | 118 (74.2) | 17 (56.7) | 70 (72.2) | 65 (70.7) | |||
| ≥ 5 | 16 (30.5) | 9 (23.1) | 41 (25.8) | 13 (43.3) | 27 (27.8) | 27 (29.3) | |||
| Pathologic T stage | 1.000 | .011 | .266 | ||||||
| pT1/pT2 | 122 (80.8) | 32 (82.1) | 134 (84.3) | 19 (63.3) | 82 (84.5) | 71 (77.2) | |||
| pT3a/pT3b/pT4 | 29 (19.2) | 7 (17.9) | 25 (15.7) | 11 (36.7) | 15 (15.5) | 21 (22.8) | |||
| Edmondson-Steiner grade | .410 | .648 | .019 | ||||||
| I/II | 36 (23.8) | 12 (30.8) | 42 (26.4) | 6 (20.0) | 32 (33) | 16 (17.4) | |||
| III/IV | 115 (76.2) | 27 (69.2) | 117 (73.6) | 24 (80.0) | 65 (67) | 76 (82.6) | |||
| Microvascular invasion | .581 | .685 | .011 | ||||||
| Absent | 94 (62.3) | 22 (56.4) | 98 (61.6) | 17 (56.7) | 68 (70.1) | 47 (51.1) | |||
| Present | 57 (37.7) | 17 (43.6) | 61 (38.4) | 13 (43.3) | 29 (29.9) | 45 (48.9) | |||
| Major vessel invasionc | .781 | .010 | .366 | ||||||
| Absent | 134 (88.7) | 34 (87.2) | 145 (91.2) | 22 (73.3) | 88 (90.7) | 79 (85.9) | |||
| Present | 17 (11.3) | 5 (12.8) | 14 (8.8) | 8 (26.7) | 9 (9.3) | 13 (14.1) | |||
Values are presented as number (%).
HCC, hepatocellular carcinomas; SALL4, Sal-like protein 4; EpCAM, epithelial cellular adhesion molecule.
a
n = 189 (tissue core loss in 1 case);
b
Size of largest tumor in case of multiple tumors;
c
Main or first order branches of portal vein and/or one or more of right, middle or left hepatic veins.